HighTower Advisors
VIVO

HighTower Advisors’s Meridian Bioscience Inc VIVO Stock Holding History

HighTower Advisors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-44,515
Closed -$1.48M – 3762
2022
Q4 		$1.48M Buy
+44,515
New +$1.43M ﹤0.01% 1446
2022
Q3 		– Sell
-8,833
Closed -$264K – 3486
2022
Q2 		$264K Buy
+8,833
New +$239K ﹤0.01% 2447
2021
Q2 		– Sell
-8,499
Closed -$224K – 3461
2021
Q1 		$224K Buy
+8,499
New +$202K ﹤0.01% 2512
2017
Q1 		– Sell
-183,196
Closed -$3.24M – 2187
2016
Q4 		$3.24M Buy
183,196
+45,522
+33% +$800K 0.04% 546
2016
Q3 		$2.65M Buy
137,674
+3,471
+3% +$67.9K 0.03% 569
2016
Q2 		$2.61M Buy
134,203
+11,888
+10% +$233K 0.03% 539
2016
Q1 		$2.52M Buy
+122,315
New +$2.41M 0.01% 634
2015
Q4 		– Sell
-111,530
Closed -$1.91M – 2158
2015
Q3 		$1.91M Buy
111,530
+34,080
+44% +$623K 0.03% 636
2015
Q2 		$1.44M Buy
77,450
+65,720
+560% +$1.22M 0.02% 633
2015
Q1 		$235K Buy
+11,730
New +$217K ﹤0.01% 1364

Other funds holding VIVO

BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

HighTower Advisors's VIVO Position: Q1 2023 in Review

HighTower Advisors sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 44,515 shares — an estimated $1.48M sold.

HighTower Advisors first reported a position in VIVO in Q1 2015 and held it in 10 quarters. The position peaked at $3.24M in Q4 2016. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

  • HighTower Advisors reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
  • HighTower Advisors sold 44,515 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.48M.
  • HighTower Advisors first reported a position in Meridian Bioscience Inc in Q1 2015 and held it in 10 quarters.
  • HighTower Advisors's Meridian Bioscience Inc position peaked at $3.24M in Q4 2016.
  • 2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on HighTower Advisors's 13F filing for Q1 2023, filed 12 May 2023.